Aptevo Therapeutics Inc.

APVO Healthcare Biotechnology

Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.62 0.08 −4.71%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
4/9
Altman Z
256174.47
Beneish M
3.69
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
1.89 3.05 3.57 3.75
Current Ratio
2.08 3.36 3.82 4.03
Net Debt/EBITDA
1.53 2.14 3.65 2.79
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.86 1.17 0.89 0.74
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(4.56) (7.51) (16.60) (29.71)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(4.56) (7.51) (16.60) (29.71)
Cash per Share
8.19 13.69 68.52 93.56
Shareholders Equity per Share
5.05 10.95 55.09 77.26
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
5.05 10.95 55.09 77.26
Free Cash Flow
(5.45) (7.96) (5.24) (6.69)
Working Capital
5.61 11.22 17.03 17.04
Net Current Asset Value
2.32 7.69 13.27 13.05
Other line items
Average Payables
2.03 2.34 1.06 2.88
Average Assets
15.07 14.12 21.39 21.07
Average Common Equity
6.28 5.07 11.07 10.91

Fold the line items

Columns are period end dates